Egetis Therapeutics AB (publ) (EGTX) - Total Assets
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) holds total assets worth Skr654.40 Million SEK (≈ $70.42 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check EGTX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Egetis Therapeutics AB (publ) - Total Assets Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s total assets have evolved over time, based on quarterly financial data. Check Egetis Therapeutics AB (publ) (EGTX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Egetis Therapeutics AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Egetis Therapeutics AB (publ)'s total assets of Skr654.40 Million consist of 48.0% current assets and 52.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 44.3% |
| Accounts Receivable | Skr23.60 Million | 3.0% |
| Inventory | Skr1.00 Million | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr408.00 Million | 51.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Egetis Therapeutics AB (publ) worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Egetis Therapeutics AB (publ)'s current assets represent 48.0% of total assets in 2024, an increase from 15.3% in 2008.
- Cash Position: Cash and equivalents constituted 44.3% of total assets in 2024, up from 13.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 51.5% of total assets.
Egetis Therapeutics AB (publ) Competitors by Total Assets
Key competitors of Egetis Therapeutics AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Egetis Therapeutics AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.56 | 7.29 |
| Quick Ratio | 1.08 | 1.55 | 7.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr19.70 Million | Skr83.20 Million | Skr141.44 Million |
Egetis Therapeutics AB (publ) - Advanced Valuation Insights
This section examines the relationship between Egetis Therapeutics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.84 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | Skr792.30 Million |
| Market Capitalization | $227.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Egetis Therapeutics AB (publ)'s assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Egetis Therapeutics AB (publ)'s assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Egetis Therapeutics AB (publ) (2008–2024)
The table below shows the annual total assets of Egetis Therapeutics AB (publ) from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr792.30 Million ≈ $85.26 Million |
+4.22% |
| 2023-12-31 | Skr760.20 Million ≈ $81.81 Million |
+35.48% |
| 2022-12-31 | Skr561.10 Million ≈ $60.38 Million |
-1.43% |
| 2021-12-31 | Skr569.27 Million ≈ $61.26 Million |
-36.32% |
| 2020-12-31 | Skr893.97 Million ≈ $96.21 Million |
+231.01% |
| 2019-12-31 | Skr270.07 Million ≈ $29.06 Million |
+11.58% |
| 2018-12-31 | Skr242.04 Million ≈ $26.05 Million |
-23.25% |
| 2017-12-31 | Skr315.37 Million ≈ $33.94 Million |
-20.45% |
| 2016-12-31 | Skr396.44 Million ≈ $42.66 Million |
+657.12% |
| 2015-12-31 | Skr52.36 Million ≈ $5.63 Million |
-49.39% |
| 2014-12-31 | Skr103.47 Million ≈ $11.13 Million |
+102.83% |
| 2013-12-31 | Skr51.01 Million ≈ $5.49 Million |
-15.62% |
| 2012-12-31 | Skr60.46 Million ≈ $6.51 Million |
-33.87% |
| 2011-12-31 | Skr91.42 Million ≈ $9.84 Million |
+976.56% |
| 2010-12-31 | Skr8.49 Million ≈ $913.91K |
+43.58% |
| 2009-12-31 | Skr5.91 Million ≈ $636.49K |
+10.12% |
| 2008-12-31 | Skr5.37 Million ≈ $578.00K |
-- |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate,… Read more